| |
| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to health benefit plan coverage of treatments for |
|
|
pediatric neuroinflammatory disorder. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Chapter 1367, Insurance Code, is amended by |
|
|
adding Subchapter H to read as follows: |
|
|
SUBCHAPTER H. PEDIATRIC NEUROINFLAMMATORY DISORDERS |
|
|
Sec. 1367.351. DEFINITIONS. In this subchapter: |
|
|
(1) "Off-label use" means the use of a prescription |
|
|
drug or therapy approved for use by the United States Food and Drug |
|
|
Administration in a manner other than the approved use. |
|
|
(2) "Pediatric neuroinflammatory disorder" means an |
|
|
immune-mediated inflammatory condition affecting the central |
|
|
nervous system in an individual younger than 18 years of age, |
|
|
including but not limited to autoimmune encephalitis, |
|
|
post-infectious encephalitis, acute disseminated |
|
|
encephalomyelitis (ADEM), optic neuritis, transverse myelitis, |
|
|
neuromyelitis optica spectrum disorder (NMOSD), pediatric |
|
|
acute-onset neuropsychiatric syndrome (PANS), pediatric autoimmune |
|
|
neuropsychiatric disorders associated with streptococcal |
|
|
infections (PANDAS), and other clinically recognized neuroimmune |
|
|
or neuroinflammatory disorders diagnosed by a physician using |
|
|
accepted clinical criteria, diagnostic testing, and clinical |
|
|
judgment. |
|
|
Sec. 1367.352. APPLICABILITY OF SUBCHAPTER. (a) This |
|
|
subchapter applies only to a health benefit plan that provides |
|
|
benefits for medical, surgical, or prescription drug expenses |
|
|
incurred as a result of a health condition, accident, or sickness, |
|
|
including an individual, group, blanket, or franchise insurance |
|
|
policy or insurance agreement, a group hospital service contract, |
|
|
or an individual or group evidence of coverage or similar coverage |
|
|
document that is issued by: |
|
|
(1) an insurance company; |
|
|
(2) a group hospital service corporation operating |
|
|
under Chapter 842; |
|
|
(3) a health maintenance organization operating under |
|
|
Chapter 843; |
|
|
(4) an approved nonprofit health corporation that |
|
|
holds a certificate of authority under Chapter 844; |
|
|
(5) a multiple employer welfare arrangement that holds |
|
|
a certificate of authority under Chapter 846; |
|
|
(6) a stipulated premium company operating under |
|
|
Chapter 884; |
|
|
(7) a fraternal benefit society operating under |
|
|
Chapter 885; |
|
|
(8) a Lloyd's plan operating under Chapter 941; or |
|
|
(9) an exchange operating under Chapter 942. |
|
|
(b) Notwithstanding any other law, this subchapter applies |
|
|
to: |
|
|
(1) a basic coverage plan under Chapter 1551; |
|
|
(2) a basic plan under Chapter 1575; and |
|
|
(3) a primary care coverage plan under Chapter 1579. |
|
|
Sec. 1367.353. COVERAGE REQUIRED. (a) A health benefit |
|
|
plan must provide coverage for the treatment of pediatric |
|
|
neuroinflammatory disorder if: |
|
|
(1) that condition was diagnosed by a physician with |
|
|
appropriate specialty training, including neurology, pediatric |
|
|
neurology, pediatric immunology, pediatric rheumatology, and an |
|
|
equivalent specialty, based on accepted clinical criteria, |
|
|
diagnostic testing, and the physician's clinical judgment; |
|
|
(2) the treatment is prescribed by the enrollee's |
|
|
treating physician as medically necessary for an individual |
|
|
diagnosed with that condition; and |
|
|
(3) the enrollee's treating physician documents, in |
|
|
the enrollee's medical record, the clinical rationale for the |
|
|
treatment and the basis for the diagnosis of that condition. |
|
|
(b) The coverage required by this section must include |
|
|
coverage of: |
|
|
(1) the following treatments: |
|
|
(A) immunomodulating therapies, including: |
|
|
(i) intravenous immunoglobulin therapy; |
|
|
(ii) rituximab; |
|
|
(iii) therapeutic plasma exchange; |
|
|
(iv) cyclophosphamide; |
|
|
(v) mycophenolate mofetil; |
|
|
(vi) azathioprine; and |
|
|
(vii) other disease-modifying therapies |
|
|
used to treat pediatric neuroinflammatory disorder under accepted |
|
|
clinical practices; |
|
|
(B) antibiotics; and |
|
|
(C) behavioral therapy; |
|
|
(2) costs related to inpatient or outpatient |
|
|
administration of a treatment described by Subdivision (1), |
|
|
including infusion services; and |
|
|
(3) any other costs associated with administering a |
|
|
treatment described by Subdivision (1), including clinical |
|
|
monitoring, laboratory testing, imaging, and other ancillary |
|
|
services. |
|
|
(c) In determining whether a treatment is medically |
|
|
necessary under this section, a health benefit plan issuer shall |
|
|
give substantial deference to the clinical judgment of the |
|
|
enrollee's treating physician who has appropriate experience in |
|
|
diagnosing or treating pediatric neuroimmune or neuroinflammatory |
|
|
disorders, taking into consideration the enrollee's clinical |
|
|
presentation, diagnostic findings, treatment history, and response |
|
|
to previous treatment. |
|
|
Sec. 1367.354. APPROVAL OF TREATMENT. A health benefit |
|
|
plan issuer may not deny or delay approval of a treatment for which |
|
|
coverage is required under Section 1367.353 on the sole basis that: |
|
|
(1) the treatment is prescribed for an off-label use |
|
|
or is classified by the health benefit plan issuer as experimental |
|
|
or investigational, if the treatment is medically necessary and |
|
|
supported by peer-reviewed medical literature, recognized clinical |
|
|
practice guidelines, or other generally accepted medical evidence |
|
|
applicable to the enrollee's condition; |
|
|
(2) the enrollee has previously received the same |
|
|
treatment for pediatric neuroinflammatory disorder or another |
|
|
diagnosis; or |
|
|
(3) the enrollee's diagnosis is listed under a |
|
|
diagnostic code or label other than pediatric neuroinflammatory |
|
|
disorder. |
|
|
Sec. 1367.355. LIMIT ON COST-SHARING REQUIREMENT. A health |
|
|
benefit plan issuer may not impose a cost-sharing requirement, |
|
|
including a copayment, coinsurance cost, or deductible for a |
|
|
treatment required to be covered under Section 1367.353 that is |
|
|
greater than the cost-sharing requirement applied to other covered |
|
|
health care services within the same benefit tier under the |
|
|
enrollee's health benefit plan. |
|
|
Sec. 1367.356. PROHIBITION ON MULTIPLE PREAUTHORIZATIONS. |
|
|
For purposes of this section, a subsequent prescription, treatment |
|
|
order, infusion, or administration of the same treatment during the |
|
|
applicable 12-month period does not constitute a new treatment |
|
|
requiring additional preauthorization solely because the treatment |
|
|
is prescribed or administered in separate doses or courses, |
|
|
provided the treatment remains medically necessary for the covered |
|
|
condition under Section 1367.353. |
|
|
Sec. 1367.357. REPORTING. (a) The department shall: |
|
|
(1) collect data on any denial or appeal of a denial of |
|
|
a treatment required to be covered under Section 1367.353; and |
|
|
(2) annually submit to the legislature a written |
|
|
report summarizing the data collected under Subdivision (1). |
|
|
(b) The department may require a health benefit plan issuer |
|
|
to submit data to the department in the form and manner prescribed |
|
|
by the commissioner for purposes of complying with this subchapter. |
|
|
SECTION 2. The changes in law made by this Act apply only to |
|
|
a health benefit plan that is delivered, issued for delivery, or |
|
|
renewed on or after January 1, 2028. |
|
|
SECTION 3. This Act takes effect September 1, 2027. |